STOCK TITAN
  1. Home
  2. News
  3. PALI

Palisade Bio, Inc. - PALI STOCK NEWS

Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.

Palisade Bio, Inc. (Symbol: PALI) is a clinical-stage biopharmaceutical company dedicated to developing therapeutic solutions aimed at preserving the integrity of the intestinal barrier. The company's primary focus is on innovative treatments for inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD).

Palisade Bio’s strategic product portfolio includes PALI-2108, a promising drug candidate currently under development for treating IBD conditions. The company is also actively researching PALI-1908, a potential therapeutic that may expand its impact in gastrointestinal health.

Recently, Palisade Bio announced significant progress in its pipeline and secured strategic partnerships to further its research and development efforts. Notably, Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the latest offering, underscoring the financial community's confidence in the company's vision and potential.

Palisade Bio's commitment to advancing healthcare solutions is backed by a robust team and dedicated research initiatives. The company frequently updates its stakeholders with the latest developments and forward-looking statements. For more information or inquiries, Jenene Thomas from the JTC Team, LLC can be contacted at 833-475-8247 or via email at PALI@jtcir.com.

News

Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference

Rhea-AI Summary
Palisade Bio CEO to participate in Virtual Investor Ask the CEO Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
-
News

Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules

Rhea-AI Summary
Palisade Bio, Inc. has closed its registered direct offering, raising $1,965,094.32 in gross proceeds. The company plans to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.48%
Tags
offering
-
News

Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer

Rhea-AI Summary
Palisade Bio appoints Mitchell Jones, M.D., Ph.D. as Chief Medical Officer. Dr. Jones has a proven track record in developing GI therapeutics. Palisade Bio aims to offer new treatment options for IBD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
management
News

Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules

Rhea-AI Summary
Palisade Bio, Inc. announces definitive agreements for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32 in a registered direct offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.83%
Tags
offering
-
News

Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

Rhea-AI Summary
Palisade Bio enters licensing agreement with Giiant Pharma for IBD therapies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
108.7%
Tags
none
-
News

Palisade Bio Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) has announced that it is accelerating late-stage corporate development activities to acquire assets for its gastrointestinal (GI) pipeline. The company reported a strong financial position with cash to fund operations through 2024. In the second quarter of 2023, Palisade Bio had cash and cash equivalents of $16.4 million. The net loss for the quarter was $3.4 million, with research and development expenses increasing by 65% compared to the same period last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
earnings
News

Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Rhea-AI Summary
Palisade Bio's Phase 2 PROFILE study evaluating LB1148 for reduction in intra-abdominal adhesions did not achieve its primary endpoint. Safety data and efficacy results do not support further development of LB1148. Palisade Bio is now focusing on pipeline expansion opportunities in high-value indications in the GI space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-62.89%
Tags
clinical trial
-
News

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
-
News

Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
News

Palisade Bio Promotes J.D. Finley to Chief Executive Officer

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
none

FAQ

What is the current stock price of Palisade Bio (PALI)?

The current stock price of Palisade Bio (PALI) is $1.43 as of January 30, 2025.

What is the market cap of Palisade Bio (PALI)?

The market cap of Palisade Bio (PALI) is approximately 4.3M.

What is Palisade Bio, Inc.'s core business?

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing therapeutics to protect the integrity of the intestinal barrier.

What diseases is Palisade Bio targeting with its therapeutics?

The company focuses on treating inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD).

What are the key products in Palisade Bio's portfolio?

Key products include PALI-2108 for IBD treatment and PALI-1908, which is currently in the research phase.

Who is the exclusive placement agent for Palisade Bio's latest offering?

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

How can I contact Palisade Bio for more information?

You can contact Jenene Thomas from the JTC Team, LLC at 833-475-8247 or via email at PALI@jtcir.com.

What stage is Palisade Bio in its development?

Palisade Bio is currently in the clinical stage of developing its therapeutic products.

Does Palisade Bio have any ongoing research projects?

Yes, Palisade Bio is actively researching PALI-1908 in addition to developing PALI-2108 for IBD treatment.

What recent achievements has Palisade Bio announced?

The company has announced significant progress in its drug pipeline and secured strategic partnerships to further research and development.

What is the significance of PALI-2108?

PALI-2108 is a promising drug candidate specifically being developed to treat inflammatory bowel diseases like UC and CD.

Who are the target stakeholders for Palisade Bio's updates?

The target stakeholders include investors, medical professionals, and partners interested in the company's advancements and therapeutic developments.
Stock PALI logo
Palisade Bio, Inc.

Nasdaq:PALI

PALI Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

PALI Stock Data

4.25M
2.74M
1.88%
3.58%
2.82%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CARLSBAD